Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant - PubMed (original) (raw)

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

J Bladé et al. Br J Haematol. 1998 Sep.

Free article

No abstract available

PubMed Disclaimer

Similar articles

• Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
  Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N. Sobh M, et al. Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. Haematologica. 2017. PMID: 28428268 Free PMC article. No abstract available.
• The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
  Kyle RA. Kyle RA. Ann Oncol. 2000;11 Suppl 1:55-8. Ann Oncol. 2000. PMID: 10707780 Review.
• High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
  Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V. Kumar L, et al. Natl Med J India. 2003 Jan-Feb;16(1):16-21. Natl Med J India. 2003. PMID: 12715951 Clinical Trial.
• Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).
  Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N. Bruno B, et al. Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Leuk Lymphoma. 2016. PMID: 26735310 Review.
• Role of hematopoietic stem cell transplantation in multiple myeloma.
  Garcia IN. Garcia IN. Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):86-91. doi: 10.1016/j.clml.2014.07.007. Epub 2014 Jul 14. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25131852 Review.

Cited by

• Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.
  Tyrna P, Procyk G, Szeleszczuk Ł, Młynarczuk-Biały I. Tyrna P, et al. Int J Mol Sci. 2024 Aug 16;25(16):8949. doi: 10.3390/ijms25168949. Int J Mol Sci. 2024. PMID: 39201634 Free PMC article. Review.
• Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution.
  Rodríguez-Lobato LG, Tovar N, de Daniel A, Fernández de Larrea C, Cibeira MT, Jiménez-Segura R, Moreno DF, Oliver-Caldés A, Bladé J, Rosiñol L. Rodríguez-Lobato LG, et al. Cancers (Basel). 2023 Nov 2;15(21):5261. doi: 10.3390/cancers15215261. Cancers (Basel). 2023. PMID: 37958434 Free PMC article.
• Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future.
  Medina-Herrera A, Sarasquete ME, Jiménez C, Puig N, García-Sanz R. Medina-Herrera A, et al. Cancers (Basel). 2023 Jul 20;15(14):3687. doi: 10.3390/cancers15143687. Cancers (Basel). 2023. PMID: 37509348 Free PMC article. Review.
• Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
  Jung EH, Byun JM, Shin DY, Do YR, Jo JC, Lee SM, Yoon SS. Jung EH, et al. Cancer Med. 2023 Apr;12(8):9186-9193. doi: 10.1002/cam4.5657. Epub 2023 Mar 23. Cancer Med. 2023. PMID: 36951655 Free PMC article.
• Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
  Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, González Vélez M, Kosiorek HE, Butterfield RDJ, Kirsch IR, Mikhael JR, Stewart AK, Reeder C, Larsen J, Bergsagel PL, Fonseca R. Fonseca R, et al. Blood Cancer J. 2023 Mar 6;13(1):32. doi: 10.1038/s41408-023-00794-x. Blood Cancer J. 2023. PMID: 36878906 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information